Extended-release brexpiprazole injection for schizophrenia
Part of Mental health clinical trials.
This trial tests a new long-acting injection of brexpiprazole, an antipsychotic that may help control schizophrenia symptoms. The study will see how the injection is absorbed, its safety, and how well people tolerate it, potentially offering a longer-lasting treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 65 years with a diagnosis of schizophrenia
- Stable on a current antipsychotic medication for at least 8 weeks
- Able to tolerate brexpiprazole (oral) without severe side effects
- No other active mental health conditions (like bipolar or major depression)
- Willing to avoid alcohol, tobacco, and certain foods/drinks (like grapefruit) during the study
- Have acceptable blood, liver, and kidney function results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new version of an extended-release injection is as effective as the original in people with schizophrenia. The study helps ensure patients have access to a reliable treatment option.
This study tests how well a new aripiprazole injection works in your body compared to a standard version. You'll receive injections while your schizophrenia symptoms are stable, and researchers will measure drug levels in your blood to ensure the new version works the same way.
This trial tests a monthly injection of cariprazine (a medication for mental health conditions) in people who could benefit from it. It aims to see if the shot is safe, tolerable, and effective compared to taking pills every day.
This trial tests a long-acting injectable form of cariprazine (AX251 LAI) for people with stable schizophrenia. You would receive one injection and stay at the clinic for 7 days to see how your body handles it and how well you tolerate it.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
This study looks at long-acting (extended-release) antipsychotic medicine options in people with schizophrenia, compared with regular tablets. You may be able to join if you were already part of a related earlier study or its real-world follow-up.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.